Masimo has received FDA clearance for a new noninvasive and continuous total hemoglobin monitoring technology (SpHb™). The availability of Masimo SpHb technology can make hemoglobin measurement more convenient and broadly available to clinicians in both hospital and outpatient settings, helping them to make earlier and better clinical decisions, improve patient safety and decrease costs. Noninvasive total hemoglobin will be offered as part of the upgradable Masimo Rainbow SET technology platform. Continuous, noninvasive hemoglobin monitoring with Masimo Rainbow SET SpHb may enable more restrictive transfusion triggers and help maintain optimal hemoglobin levels for critically-ill patients. In addition to facilitating better blood level management, Masimo Rainbow SET’s noninvasive hemoglobin monitoring capability should also help clinicians better manage chronic anemia.